This week in therapeutics




Licensing status

Publication and contact information

Infectious disease

Gram-negative bacterial infection

Capsular polysaccharide export protein (wza)

Cell culture studies identified a glycomimetic inhibitor of wza that could help treat Gram-negative bacterial infections. An in vitro screen identified an unnatural cyclic glycomimetic that could inhibit wza activity by blocking the protein's a-helix barrel. In a pathogenic strain of Escherichia coli cultured in human serum, the glycomimetic blocked the transport of a capsular polysaccharide and caused defects in the bacterial outer membrane, and it increased complement-mediated killing of bacteria compared with no treatment. Next steps include evaluating the glycomimetic in animal models.

SciBX 6(29); doi:10.1038/scibx.2013.761
Published online Aug. 1, 2013

Patent application filed; available for licensing from Isis Innovation Ltd.
Contact: Mark Gostock, Isis Innovation Ltd., Oxford, U.K.

Kong, L. et al. Nat. Chem.; published online June 30, 2013;
Contact: Hagen Bayley, University of Oxford Chemical Research Laboratory, Oxford, U.K.

Contact: Benjamin G. Davis, same affiliation as above